NeuroSense Therapeutics Ltd. (NRSN) stock
NRSNNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NRSNW
$1.37−0.14 (-9.27%)
Close on Nov 18, 2026Market cap $2.52MP/E –Yield –
NeuroSense Therapeutics cash
Cash and short-term investments held at the end of each period.
NeuroSense Therapeutics's cash was $231.00K at Jun 30, 2026. For fiscal 2025 it was $166.00K, down 95.1% from the year before. The highest annual figure on record is $11.06M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $166.00K | -95.1% |
| FY2024 | Dec 31, 2024 | $3.38M | +28.0% |
| FY2023 | Dec 31, 2023 | $2.64M | -25.5% |
| FY2022 | Dec 31, 2022 | $3.54M | -68.0% |
| FY2021 | Dec 31, 2021 | $11.06M | +1482.7% |
| FY2020 | Dec 31, 2020 | $699.00K | -21.9% |
| FY2019 | Dec 31, 2019 | $895.00K | +940.7% |
| FY2018 | Dec 31, 2018 | $86.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $231.00K | -80.9% |
| Q4 FY2025 | Dec 31, 2025 | $166.00K | -93.7% |
| Q2 FY2025 | Jun 30, 2025 | $666.00K | -90.6% |
| Q4 FY2024 | Dec 31, 2024 | $3.38M | -4.7% |
| Q2 FY2024 | Jun 30, 2024 | $1.21M | -72.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.64M | -76.1% |
| Q2 FY2023 | Jun 30, 2023 | $7.09M | +613.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.54M | +406.9% |
| Q2 FY2022 | Jun 30, 2022 | $4.35M | +385.9% |
| Q4 FY2021 | Dec 31, 2021 | $11.06M | +12764.0% |
| Q2 FY2021 | Jun 30, 2021 | $994.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $699.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $895.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $86.00K | – |
See a number that looks wrong?